AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19905952 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Number of subjects: 80
Study 19905952 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic curet
Number of subjects: 80
Study 19905952 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal curet
Number of subjects: 80
Study 19905952 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-powder abrasive system
Number of subjects: 80
Study 19905952 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated specimens)
Number of subjects: 80
Study 16713457 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 31
Study 16713457 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 31
Study 15016027 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% SLS-containing dentifrice and 0.2% CHX mouthrinse (regimen 1)
Number of subjects: 16
Study 15016027 — intervention group
Group type: COMPARATOR
Intervention: 0.2% CHX mouthrinse only (regimen 2)
Number of subjects: 16
Study 11336164 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐1beta (10 ng/ml)
Number of subjects: 0
Study 11336164 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐1alpha, IL‐1beta, TNF, PMA, LPS
Number of subjects: 0
Study 11336164 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF and IL‐1
Number of subjects: 0
Study 11336164 — intervention group
Group type: EXPERIMENTAL
Intervention: ALLN (proteasome and NF‐kappaB activation inhibitor)
Number of subjects: 0
Study 11336164 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐4 and IL‐10
Number of subjects: 0
Study 11336164 — intervention group
Group type: COMPARATOR
Intervention: Control patients vs patients with mucosal inflammation
Number of subjects: 0
Study 9124069 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids (BCAAs)
Number of subjects: 7
Study 9124069 — intervention group
Group type: COMPARATOR
Intervention: Flavoured water (placebo)
Number of subjects: 7
Study 7653743 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% sodium cromoglycate
Number of subjects: 12
Study 7653743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3030090 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% sucrose addition to cooked dried butter beans
Number of subjects: 40
Study 3030090 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% sucrose addition to cooked dried butter beans
Number of subjects: 40
Study 3030090 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% sucrose addition to cooked dried butter beans
Number of subjects: 40
Study 3030090 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sucrose addition)
Number of subjects: 40
Study 30581161 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic entecavir (ETV) before chemotherapy and at least 6 months after completion of chemotherapy
Number of subjects: 190
Study 30581161 — intervention group
Group type: COMPARATOR
Intervention: Regular monitoring alone (control)
Number of subjects: 190
Study 29176824 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze-dried trivalent antivenom (FDTAV)
Number of subjects: 116
Study 29176824 — intervention group
Group type: COMPARATOR
Intervention: Standard liquid antivenom (SLAV)
Number of subjects: 116
Study 26160997 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TMS (10 sessions of 10 Hz rTMS at 110% of motor threshold, 2,000 pulses per session)
Number of subjects: 34
Study 26160997 — intervention group
Group type: COMPARATOR
Intervention: Sham TMS (control group)
Number of subjects: 34
Study 23150919 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine 90 mg/m² plus Bortezomib 1.0 mg/m²
Number of subjects: 40
Study 23150919 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine 50, 70, or 90 mg/m² plus Bortezomib 1.0 mg/m²
Number of subjects: 40
Study 23150919 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine plus Bortezomib
Number of subjects: 40
Study 21214899 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhale® Drug‐Eluting Stent
Number of subjects: 450
Study 21214899 — intervention group
Group type: COMPARATOR
Intervention: Sham bronchoscopy
Number of subjects: 450
Study 18957146 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung recruitment maneuvers (RMs) performed twice daily for 3 days, starting at 35 cm H(2)O for 20 seconds, with potential increases to 40 cm H(2)O and 45 cm H(2)O or longer durations (30 seconds, then 40 seconds) if needed.
Number of subjects: 28
Study 18957146 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled lung recruitment maneuvers (RMs)
Number of subjects: 28
Study 16581613 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants (combination tablet of vitamins A, C, and E)
Number of subjects: 798
Study 16581613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 798
Study 15023671 — intervention group
Group type: EXPERIMENTAL
Intervention: High dairy protein (DP, 2400mg Ca/d)
Number of subjects: 50
Study 15023671 — intervention group
Group type: COMPARATOR
Intervention: High mixed protein (MP, 500mg Ca/d)
Number of subjects: 50
Study 10955434 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg oestradiol implants
Number of subjects: 44
Study 10955434 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg oestradiol implants
Number of subjects: 44
Study 8624267 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil 500 mg m‐2, epidoxorubicin 120 mg m‐2, cyclophosphamide 500 mg m‐2 (FE120C) administered at 21 day intervals without haematopoietic growth factors
Number of subjects: 70
Study 1361718 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenergic blocker treatment
Number of subjects: 0
Study 6426493 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.45 mg kg‐1
Number of subjects: 20
Study 6426493 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium 0.1 mg kg‐1
Number of subjects: 20
Study 27387971 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl (2 μg/kg; maximum, 100 μg)
Number of subjects: 20
Study 27387971 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl
Number of subjects: 20
Study 27387971 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine (0.1 mg/kg; maximum, 8 mg)
Number of subjects: 20
Study 29652460 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-controlled injection system
Number of subjects: 60
Study 29652460 — intervention group
Group type: COMPARATOR
Intervention: Conventional syringe
Number of subjects: 60
Study 25899007 — intervention group
Group type: EXPERIMENTAL
Intervention: OBE001 600 mg/day
Number of subjects: 12
Study 25899007 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone 12 mg/day
Number of subjects: 12
Study 25899007 — intervention group
Group type: EXPERIMENTAL
Intervention: OBE001 and Betamethasone combination
Number of subjects: 12
Study 25899007 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 12
Study 23964387 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation for 6 months
Number of subjects: 691
Study 23964387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 691
Study 21904204 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon α‐2a (40 KD) 180 µg/week plus ribavirin (800 mg/day) for 24 weeks
Number of subjects: 789
Study 21904204 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon α‐2a (40 KD) 180 µg/week plus ribavirin (1000/1200 mg/day) for 48 weeks
Number of subjects: 789
Study 21904204 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment with peginterferon α‐2a (40 KD) plus ribavirin
Number of subjects: 789
Study 18928387 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatin-sealant-assisted tubeless PCNL
Number of subjects: 50
Study 18928387 — intervention group
Group type: COMPARATOR
Intervention: Tubeless PCNL without gelatin
Number of subjects: 50
Study 17220050 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (single oral dose) under fed condition (after a standardized high fat breakfast)
Number of subjects: 0
Study 17220050 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (single oral dose) under fasted condition
Number of subjects: 0
Study 17220050 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (single oral dose) under fed condition
Number of subjects: 0
Study 15626006 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical cricothyrotomy
Number of subjects: 22
Study 15626006 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous cricothyrotomy
Number of subjects: 22
Study 10686371 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 0
Study 9088811 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 4.0 mg kg‐1
Number of subjects: 100
Study 9088811 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate 7.5 micrograms kg‐1
Number of subjects: 100
Study 9088811 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate 40 mg kg‐1
Number of subjects: 100
Study 9088811 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 1.5 mg kg‐1
Number of subjects: 100
Study 9088811 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 100
Study 7515193 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 10(6) KIU aprotinin (1 x 10(6) as a loading dose before cardiopulmonary bypass, 1 x 10(6) in the priming volume and 2.5 x 10(5)/hour intraoperatively)
Number of subjects: 40
Study 7515193 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (reduced dosage)
Number of subjects: 40
Study 3528891 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP intranasally starting at 30 micrograms per day increasing to 180 micrograms per day
Number of subjects: 14
Study 3528891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 29737802 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamon (3 capsules of 500 mg each daily for 8 weeks)
Number of subjects: 84
Study 29737802 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamon
Number of subjects: 84
Study 29737802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 27130723 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-like transcutaneous nerve stimulation (ALTENS)
Number of subjects: 27
Study 27130723 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 27
Study 25346054 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo session (deceptive instructions regarding administration of an analgesic drug)
Number of subjects: 30
Study 25346054 — intervention group
Group type: COMPARATOR
Intervention: Control session (truthful information about an inert substance)
Number of subjects: 30
Study 25346054 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo session
Number of subjects: 30
Study 22220591 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (3mg, p.o., n=13)
Number of subjects: 18
Study 22220591 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=5)
Number of subjects: 18
Study 19762549 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to a counselor
Number of subjects: 226
Study 19762549 — intervention group
Group type: EXPERIMENTAL
Intervention: Information about spiritual services
Number of subjects: 226
Study 17868057 — intervention group
Group type: EXPERIMENTAL
Intervention: sirolimus
Number of subjects: 145
Study 15685254 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen ('Nolvadex') 20 mg/day
Number of subjects: 107
Study 15685254 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole ('Arimidex') 1 mg/day
Number of subjects: 107
Study 15685254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 11789790 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive technique (group A)
Number of subjects: 255
Study 11789790 — intervention group
Group type: COMPARATOR
Intervention: Traditional technique (group B)
Number of subjects: 255
Study 9433653 — intervention group
Group type: EXPERIMENTAL
Intervention: Grepafloxacin 400 mg, daily for 7 days
Number of subjects: 36
Study 8438003 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDS education unit
Number of subjects: 103
Study 8438003 — intervention group
Group type: COMPARATOR
Intervention: No AIDS education unit (control group)
Number of subjects: 103
Study 3803106 — intervention group
Group type: EXPERIMENTAL
Intervention: Urecholine (oral or subcutaneous)
Number of subjects: 108
Study 3803106 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 108
Study 3803106 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fluids
Number of subjects: 108
Study 29655971 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsychosocial model of violence risk assessment (including V-RISK-10, SRS, TC, HDL)
Number of subjects: 348
Study 29655971 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL
Number of subjects: 348
Study 29655971 — intervention group
Group type: EXPERIMENTAL
Intervention: SRS
Number of subjects: 348
Study 27981956 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 0
Study 27981956 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy
Number of subjects: 0
Study 23910821 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific instrumentation (PSI)
Number of subjects: 52
Study 23910821 — intervention group
Group type: COMPARATOR
Intervention: Traditional instrumentation (TI)
Number of subjects: 52
Study 23910821 — intervention group
Group type: COMPARATOR
Intervention: Patient-specific instrumentation (PSI) vs Traditional instrumentation (TI)
Number of subjects: 52
Study 21489005 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin
Number of subjects: 1015
Study 21489005 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 1015
Study 21489005 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1015
Study 19223546 — intervention group
Group type: EXPERIMENTAL
Intervention: High intake of DiMeIQx
Number of subjects: 2253
Study 19223546 — intervention group
Group type: EXPERIMENTAL
Intervention: High intake of MeIQx
Number of subjects: 2253
Study 19223546 — intervention group
Group type: COMPARATOR
Intervention: Low intake of DiMeIQx
Number of subjects: 2253
Study 19223546 — intervention group
Group type: COMPARATOR
Intervention: Low intake of MeIQx
Number of subjects: 2253
Study 15901655 — intervention group
Group type: EXPERIMENTAL
Intervention: Attended walker
Number of subjects: 0
Study 15901655 — intervention group
Group type: COMPARATOR
Intervention: Ignored walker
Number of subjects: 0
Study 15901655 — intervention group
Group type: EXPERIMENTAL
Intervention: Attended configurations (canonical and scrambled)
Number of subjects: 0
Study 12920411 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (30‐45 mg/d)
Number of subjects: 345
Study 12920411 — intervention group
Group type: COMPARATOR
Intervention: Sertraline (50‐150 mg/d)
Number of subjects: 345
Study 12920411 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 345
Study 12920411 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine and Sertraline
Number of subjects: 345
Study 10843485 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT) with non-conjugated estrogens, mean duration of HRT was 25 months, starting on average 18 months after completed therapy for ovarian cancer.
Number of subjects: 31
Study 9282183 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation under Bier's block
Number of subjects: 30
Study 9282183 — intervention group
Group type: COMPARATOR
Intervention: Plaster immobilization alone
Number of subjects: 30
Study 7509399 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 1:100,000 adrenaline and 5% ethanolamine injection
Number of subjects: 70
Study 7509399 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 70
Study 3300138 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 170
Study 3300138 — intervention group
Group type: EXPERIMENTAL
Intervention: Entonox
Number of subjects: 170
Study 3300138 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine + Promazine
Number of subjects: 170
Study 3300138 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar Epidural
Number of subjects: 170
Study 30102447 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular delayed gadolinium-enhanced MRI of menisci (dGEMRIM)
Number of subjects: 85
Study 30102447 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular delayed gadolinium-enhanced MRI of cartilage (dGEMRIC)
Number of subjects: 85
Study 30102447 — intervention group
Group type: EXPERIMENTAL
Intervention: T1 relaxation times for cartilage, lateral menisci, and medial menisci
Number of subjects: 85
Study 30102447 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of dGEMRIM between different morphology sum scores
Number of subjects: 85
Study 27497768 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone with yohimbine
Number of subjects: 16
Study 27497768 — intervention group
Group type: COMPARATOR
Intervention: Yohimbine alone
Number of subjects: 16
Study 26341547 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 200 μg beclomethasone dipropionate (BDP) in standard posture
Number of subjects: 32
Study 26341547 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 200 μg beclomethasone dipropionate (BDP) in forward leaning posture
Number of subjects: 32
Study 24083590 — intervention group
Group type: EXPERIMENTAL
Intervention: HHPG‐19K 60 μg/kg/day
Number of subjects: 30
Study 24083590 — intervention group
Group type: EXPERIMENTAL
Intervention: HHPG‐19K 100 μg/kg/day
Number of subjects: 30
Study 24083590 — intervention group
Group type: EXPERIMENTAL
Intervention: HHPG‐19K 200 μg/kg/day
Number of subjects: 30
Study 24083590 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim (G‐CSF) 5 μg/kg/day
Number of subjects: 30
Study 24083590 — intervention group
Group type: COMPARATOR
Intervention: Negative control group
Number of subjects: 30
Study 19365087 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 99
Study 19365087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 18844721 — intervention group
Group type: EXPERIMENTAL
Intervention: High-emollient body wash
Number of subjects: 0
Study 18844721 — intervention group
Group type: COMPARATOR
Intervention: Regular bar cleanser
Number of subjects: 0
Study 21511219 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg/day
Number of subjects: 71
Study 21511219 — intervention group
Group type: COMPARATOR
Intervention: High-dose clopidogrel 150 mg/day
Number of subjects: 71
Study 21511219 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg/day (in carriers of CYP2C19*2)
Number of subjects: 71
Study 21511219 — intervention group
Group type: COMPARATOR
Intervention: High-dose clopidogrel 150 mg/day (in carriers of CYP2C19*2)
Number of subjects: 71
Study 21511219 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg/day (in noncarriers of CYP2C19*2)
Number of subjects: 71
Study 21511219 — intervention group
Group type: COMPARATOR
Intervention: High-dose clopidogrel 150 mg/day (in noncarriers of CYP2C19*2)
Number of subjects: 71
Study 16191668 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine and carbamazepine
Number of subjects: 26
Study 16191668 — intervention group
Group type: COMPARATOR
Intervention: Methadone and carbamazepine
Number of subjects: 26
Study 11831540 — intervention group
Group type: COMPARATOR
Intervention: Retigabine (200, 400, 500, and 600 mg per day fixed doses; 700 mg per day titrated doses)
Number of subjects: 45
Study 11831540 — intervention group
Group type: EXPERIMENTAL
Intervention: Retigabine (titrated doses up to 700 mg per day)
Number of subjects: 45
Study 11831540 — intervention group
Group type: EXPERIMENTAL
Intervention: Retigabine (multiple doses)
Number of subjects: 45
Study 11831540 — intervention group
Group type: EXPERIMENTAL
Intervention: Retigabine (in white subjects)
Number of subjects: 45
Study 11831540 — intervention group
Group type: EXPERIMENTAL
Intervention: Retigabine (in black subjects)
Number of subjects: 45
Study 9702467 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg bd)
Number of subjects: 24
Study 9702467 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8309562 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous immunoglobulin (IVIg)
Number of subjects: 13
Study 2468912 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 2468912 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0
Study 2468912 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0
Study 2468912 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 0
Study 29798776 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-Eluting Stents (EES)
Number of subjects: 309
Study 29798776 — intervention group
Group type: COMPARATOR
Intervention: Drug-Eluting Balloons (DEB)
Number of subjects: 309
Study 26979849 — intervention group
Group type: EXPERIMENTAL
Intervention: Boston psychiatric rehabilitation approach (bpr)
Number of subjects: 156
Study 26979849 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (cau)
Number of subjects: 156
Study 25898343 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural Activation (BA)
Number of subjects: 100
Study 25898343 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant Medication (ADM)
Number of subjects: 100
Study 23407019 — intervention group
Group type: EXPERIMENTAL
Intervention: HFCWO
Number of subjects: 107
Study 23407019 — intervention group
Group type: COMPARATOR
Intervention: PEP
Number of subjects: 107
Study 20939913 — intervention group
Group type: EXPERIMENTAL
Intervention: Program led by a clinical pharmacist trained in motivational interviewing‐based behavioral counseling approaches and authorized to make BP medication changes
Number of subjects: 5
Study 20939913 — intervention group
Group type: EXPERIMENTAL
Intervention: Program led by a clinical pharmacist
Number of subjects: 5
Study 20939913 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 5
Study 18632838 — intervention group
Group type: EXPERIMENTAL
Intervention: Headgear (HG) treatment initiated immediately
Number of subjects: 68
Study 18632838 — intervention group
Group type: COMPARATOR
Intervention: Control group with only minor interceptive procedures
Number of subjects: 68